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The provision of non-needle/syringe drug
injecting paraphernalia in the primary prevention
of HCV among IDU: a systematic review
Michelle Gillies1*, Norah Palmateer2, Sharon Hutchinson2,3, Syed Ahmed4, Avril Taylor5, David Goldberg2
Abstract
Background: Sharing drug injecting paraphernalia other than needles and syringes (N/S) has been implicated in
the transmission of Hepatitis C virus (HCV) among injecting drug users (IDU). We aimed to determine whether the
provision of sterile non-N/S injecting paraphernalia reduces injecting risk behaviours or HCV transmission among
IDU.
Methods: A systematic search of seven databases and the grey literature for articles published January 1989-
February 2010 was undertaken. Thirteen studies (twelve observational and one non-randomized uncontrolled pilot
intervention) were identified and appraised for study design and quality by two investigators.
Results: No studies examined the association between the provision of non-N/S injecting paraphernalia and
incident HCV infection. One cross-sectional study found that individuals who frequently, compared to those who
infrequently, used sterile cookers and water, were less likely to report prevalent HCV infection. Another found no
association between the uptake of sterile non-N/S injecting paraphernalia and self-reported sharing of this
paraphernalia. The remaining observational studies used attendance at needle and syringe exchange programmes
(NSP) or safer injection facilities (SIF) that provided non-N/S injecting paraphernalia as a proxy measure. Eight
studies presented adjusted odds ratios, ranging from 0.3 to 0.9, suggesting a reduced likelihood of self-reported
sharing of non-N/S injecting paraphernalia associated with use of NSP or SIF. There was substantial uncertainty
associated with these estimates however. Three unadjusted studies reported a reduction in the prevalence of
sharing of non-N/S injecting paraphernalia over time among NSP users. Only one study reported an adjusted
temporal trend in the prevalence of sharing non-N/S injecting paraphernalia, finding higher rates among non-NSP
users than NSP users at each time point, and a greater reduction in sharing among non-NSP than NSP users over
time. Study limitations included the use of convenience samples, self-reported exposure and outcome measures,
flawed classification of the exposed and unexposed groups, and inadequate adjustment for potential confounding
variables.
Conclusions: The evidence to demonstrate that the provision of sterile non-N/S injecting paraphernalia reduces
HCV transmission or modifies injecting risk behaviours is currently limited by an insufficient volume and quality of
studies. Further research is required to inform practice and policy in this area.
Background
The sharing of drug injecting paraphernalia, equipment
used in the preparation and administration of drugs for
injection, is common and has been implicated in the
transmission of Hepatitis C (HCV) [1-3]. There is
compelling evidence that HCV transmission occurs
through the sharing of contaminated needles and syr-
inges (N/S). This is biologically plausible; in the act of
preparing and administering drugs for injection, N/S
will generally come into direct contact with blood. The
prevalence of HCV is high among those who report
injecting drug use [4] and the risk of HCV transmission
has been independently documented in studies of nee-
dle-stick injury in health care workers [5,6].
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Evidence relating to the risk of HCV transmission
associated with sharing non-N/S injecting paraphernalia
is less well established however. Ethnographic studies
have highlighted numerous opportunities for cross-
contamination to occur when individuals share drug
preparation equipment other than N/S [7-10]. Labora-
tory studies have isolated HCV RNA from injecting
equipment including spoons used as drug cookers (also
called stericups), filters (also called cottons or sterifilts)
and water samples [11]. The self-reported sharing of
such items of paraphernalia is high, irrespective of the
setting or population studied. Between 65% to 84%, 50%
to 77%, and 15% to 83% of intravenous drug users
(IDU) report sharing drug cookers, filters and water,
respectively [12].
To date, few longitudinal observational studies have
detected an association between HCV incidence and the
sharing of non- N/S injecting paraphernalia. A recent
systematic review concluded that evidence relating the
sharing of such drug injecting paraphernalia to HCV
transmission was ‘not overwhelming’ and highlighted
several methodological limitations of the studies that
contribute to this evidence base [13]. A high baseline
prevalence of HCV among IDU and poor study reten-
tion has limited the statistical power that many studies
have had to detect an association between incident HCV
infection and isolated, often highly correlated, injecting
practices.
In the United Kingdom (UK) primary and secondary
health care is provided, free at point of access, by the
National Health Service (NHS). Local authorities are
responsible for meeting nationally agreed targets on
health and social care but retain considerable autonomy
over the allocation of resources. Following legislative
change in 2003, N/S exchange programmes (NSP) in the
UK are now able to provide clients with sterile items of
drug injecting paraphernalia in addition to N/S. There is
however wide local and regional variation in the provi-
sion of such paraphernalia by NSP [14,15]. The effec-
tiveness, and indeed cost-effectiveness, of providing of
sterile injecting paraphernalia other than needles and
syringes in the primary prevention of HCV among IDU
has yet to be established [16]. To inform future public
health policy and practice in the UK and elsewhere, we
conducted a systematic review to determine whether the
distribution of sterile drug injecting paraphernalia other
than needles and syringes reduces the risk of HCV
transmission or modifies injecting risk behaviours.
Methods
We searched MEDLINE, MEDLINE In- Process &
Other Non-Indexed Citations, Cochrane Central Regis-
ter of Controlled Trials, Cochrane Database of Systema-
tic Reviews, Database of Abstracts of Reviews of Effects,
EMBASE and PsycINFO for articles published between
January 1989 and February 2010 using the search strat-
egy outlined in Appendix 1. The grey literature was
searched using the terms ‘Hepatitis C’ or ‘HCV’ and
‘paraphernalia’. Reference lists of selected articles were
reviewed and citation checks carried out to identify
further potentially relevant studies. Two investigators
(MG, NP) reviewed the abstracts of potentially eligible
articles to determine relevance; where relevant full texts
were retrieved and examined.
Inclusion and exclusion criteria
Injecting paraphernalia was defined as equipment used
in the preparation or administration of drugs for injec-
tion. For the purposes of this review we limited this
definition to drug cookers, filters and water, as these are
the items of injecting paraphernalia most likely to be
contaminated with blood in the course of preparing or
administering drugs [7-10]. The exposure of interest was
the distribution of drug cookers, filters and/or water;
however, the self-reported uptake of these items or the
use of an NSP or safer injection facility (SIF) that pro-
vided these items was accepted as a proxy measure of
exposure. Studies that did not provide one or more of
these items of paraphernalia or that did not explicitly
state which items of paraphernalia were provided, were
excluded. The outcomes of interest were (i) incident
HCV infection (ii) prevalent HCV infection and (iii)
injecting risk behaviours, namely the self-reported shar-
ing of drug cookers, filters and/or water. The study
population of interested was current IDU. Descriptive
studies, qualitative studies, review articles, editorials and
opinion pieces were excluded. Only primary research
studies were considered. Where two or more articles
presented data from the same cohort during overlapping
time frames, the publication with the largest sample size
was selected for inclusion.
Study Appraisal
We used the STROBE [17] criteria as a guide to con-
sider key aspects of study design: sampling methods,
definition of study population, inclusion and exclusion
criteria, assessment of exposure, assessment of outcome
(s), completeness of follow-up, treatment of missing
data and treatment of possible confounding variables.
Each item was assessed in terms of how well the area
was addressed and reported by investigators in relation
to the aims of this review. Study quality was assessed
independently by two reviewers (MG, NP) with dis-
agreement resolved by a third reviewer (SH).
Results
From the 794 citations retrieved fourteen studies met
the inclusion criteria (Figure 1). Following appraisal, one
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unpublished cross-sectional study was rejected [18]. The
remaining studies - five cohort studies [19-23], one
serial cross-sectional study [24], six cross-sectional stu-
dies [25-30] and one non-randomised intervention study
[31] - were conducted in North America (11 in the USA
[19-21,23,24,26-31] and two in Canada [22,25]) between
1992 and 2005 (Table 1). With one exception [30], all
examined the association between use of an NSP (includ-
ing secondary exchange of N/S [28]) or SIF [22] at which
sterile non- N/S injecting paraphernalia were available,
and the self-reported sharing of this equipment. We did
not identify any studies reporting the risk of incident
HCV infection in relation to the use of sterile injecting
paraphernalia; however, one cross-sectional study
reported the likelihood of using sterile drug cookers and
sterile water according to self-reported HCV status [25].
Study Quality
The major methodological limitations identified include
the use of convenience samples [20,25-28], self-reported
exposure and outcome measures [19-30], the use
of NSP (or SIF) as a proxy measure for use of sterile
non- N/S injecting equipment [19-24,26-31], in some
cases with inadequate assessment of exposure to NSP
[20,27,28] and statistical analyses which failed to adjust
for potential confounding variables [23,24,27,29,30]
(Table 1). None of the cohort studies identified under-
took traditional cohort analyses [19-23]. Participation
rates (reported in 5 studies) varied from 70% to 100%
and losses to follow up (reported in 4 of the 5 cohort
studies) ranged from 27% to 56%. The only non-obser-
vational study was a small (n = 37) uncontrolled non-
randomized pilot intervention trial [31].
Cohort Studies
Five cohort studies examining over 5,000 IDU between
1994 and 2005 were included in this review [19-23]
(Table 2). The largest study followed 2,814 IDU,
recruited in Seattle, USA from 1994 through 1997, over
a one year period [19]. The authors found no significant
difference in the sharing of ‘cookers or cottons’ in the
month prior to follow-up interview between those who
reported ‘ever’ compared to ‘never’ using an NSP at
study enrolment, with an adjusted odds ratio (AOR) of
0.79 (95% CI 0.58 - 1.08). Huo et al documented a high
prevalence of sharing ‘other injecting paraphernalia’ in
the 30 days prior to interview in both NSP users (60%)
and nonusers (70%) at baseline in their cohort of 901
IDU recruited in Chicago, USA between 1997 and 2000
[20]. Across the 3 year study the self-reported preva-
lence of sharing ‘other injecting paraphernalia’ fell to
almost identical levels in both NSP users and nonusers
(approximately 22%). Following adjustment, NSP users
were less likely, across all study visits, to report sharing
‘other injecting paraphernalia’ in the preceding month
compared to non-users (AOR 0.7, (0.52 - 0.95)). Sears
and colleagues compared the self-reported sharing of
‘cottons, cookers or water’ in the 30 days prior to inter-
view at baseline, 6 months and 1 year follow up in NSP
users (n = 132) and non-users (n = 97) recruited in San
Francisco, USA in 1993 [21]. Due to differential attrition
rates according to NSP status, bivariate analyses were
limited to cases that completed all three interviews (n =
101, 44% of the study population). NSP users were “sig-
nificantly” more likely than non-users to report sharing
a ‘cotton, cooker or water’ at baseline (61% NSP users
vs. 40% non-users, p value not reported). A decline in
the prevalence of sharing a ‘cotton, cooker or water’ at
follow up was reported in both NSP users (to approxi-
mately 55% at 6 months and 45% at 1 year) and nonu-
sers (to approximately 40% at 6 months and 30% at
1 year); p-values were not provided. In multivariate ana-
lyses there was an interaction between NSP status by
study visit for the sharing of a ‘cotton, cooker or water’
was reported. AOR stratified by NSP status were not
presented, however the authors concluded “nonexchan-
gers showed a larger decrease than exchangers in this
behaviour over time.” More contemporaneous data
(2004 - 2005) from Vancouver, Canada explored
changes in injection practices associated with use of a
medically supervised safer injection facility (SIF) [22].
Consistent SIF users (n = 433) - individuals that
reported using the SIF for greater than 25% of all inject-
ing episodes - were more likely than inconsistent users
(n = 327) to report a change to using clean water for
injecting since they started using the SIF (AOR 2.99
(2.13 - 4.18)). Lastly, Vlahov and colleagues carried out
a before -after study following a cohort of 422 IDU
Figure 1 Inclusion and exclusion of studies through the review
process.
Gillies et al. BMC Public Health 2010, 10:721
http://www.biomedcentral.com/1471-2458/10/721
Page 3 of 14
Table 1 Summary of studies included in review following appraisal
Reference Design Setting Study Population Data Collected Study Limitations
Hagan et al.
2000 [19]
Cohort Seattle, USA
Recruitment:
1994 - 1997
Random sample of IDU
recruited from locations other
than NSP including prisons,
street outreach, social services
and drug treatment
programmes. 2,814 IDU aged 14
years or older who had injected
elicit drugs in the last year of
whom 2,208 (78.5%) completed
a follow-up interview. NSP users
(n = 1236) had ‘ever’ used the
NSP in the period prior to
enrolment; non-users (n = 346)
had ‘never’ used NSP prior to.
IDU paid to participate. The NSP
provided drug cookers, cottons
and rinse water.
Exposure: NSP use (’Ever’ vs.
‘Never’) defined at study
enrolment.
Outcome: Self-reported sharing
of ‘cookers or cottons’ in the
month and six months prior to
study enrolment. Thereafter
behaviours in the month prior
to follow up.
Data collected by interview
administered questionnaire at
baseline and follow up visit at 1
year.
Dichotomous measure of NSP use
‘ever’ vs. ‘never’ does not allow for
gradations in use. NSP use at
baseline may not represent NSP use
at follow up.
Self-reported outcome measures.
Statistical analyses were carried out
on 71.6% (n = 1,582) participants
who completed a follow up visit,
representing 56.2% of all eligible
participants enrolled at baseline. The
authors report no association
between study retention and NSP
use or injecting risk behaviour,
however high loss to follow up may
have reduced statistical power.
Huo et al
2007 [20]
Cohort Chicago,
USA
Recruitment:
1997 - 2000
Convenience sample of IDU
that had injected in the last 6
months and were aged 18 years
or older. Verification of age and
recent IDU required. Regular
NSP users (n = 729) recruited at
NSP (multisite). Non NSP users
(n = 172), individuals who had
not used a NSP in the 6 months
prior to study enrolment, were
recruited from a ‘control’ area
without local NSP services via
street outreach and peer
referral. The NSP supplied
cotton, cookers, alcohol wipes
and water. Non-users had
access to cookers.
Exposure: NSP use (Regular vs.
non NSP users) defined at study
enrolment.
Outcome: Self-reported
prevalence of sharing ‘other’
injecting paraphernalia in the 30
days prior to interview. This
composite endpoint was used
to denote the sharing of any
single item of non-N/S
paraphernalia.
Data collected by interview
administered questionnaire at
baseline and three annual
follow up visits.
Convenience sampling
Differential sampling method NSP
users and non-users.
Dichotomous measure of NSP use
does not allow for gradations in use.
NSP use defined at baseline may not
represent NSP use at follow up.
Both NSP users and non-users had
access to sterile injecting
paraphernalia thereby limiting
comparison between groups.
Self-reported outcome measures
Follow up data available on 83.7% (n
= 610) NSP users and 75.6% (n =
130) non NSP users (did not differ
according to risk behaviour at
baseline).
Sears et al.
2001 [21]
Cohort San
Francisco,
USA.
Recruitment:
July 1993
NSP users recruited using
systematic sampling (every nth
person) of IDU attending NSP in
three locations. Non-users were
recruited using a targeted
sampling method through an
ongoing multi-wave cross-
sectional behavioural study that
included HIV testing and
counselling (the Urban Health
Study). Participation rate for NSP
users 88%, for non-users 84%.
NSP status subsequently
reclassified according to
reported NSP use at baseline
rather than recruitment site.
NSP users (n = 132) reported at
least one use of NSP in the last
30 days and at least one
additional use of NSP in the
preceding 6 months. Non-users
(n = 97) reported no use of NSP
in the past 30 days or the
preceding 6 months.
IDU paid to participate. The NSP
provided cottons and alcohol
swabs.
Exposure: NSP use (NSP use vs.
non use) defined at study
enrolment.
Outcome: Self-reported sharing
of cotton, cooker or water in
the preceding 30 days.
Data collected during structured
interviews at baseline, 6 month
and 12 month follow up.
Differential sampling methods in
recruitment of NSP users and non-
users (possible selection bias).
Although the outcome measure was
sharing of cottons, cookers or water,
participants only had access to
cottons and alcohol swabs from
NSP.
Dichotomous measure of NSP use
excludes gradations in use. NSP use
at baseline may not reflect NSP use
at follow-up.
Self-reported outcome measures.
Follow up data collected on 49%
and 57% of participants at 6 and 12
month visits respectively. Differential
follow up according to NSP use; in
the non-users group those lost to
follow up reported higher risk
injecting behaviours. Bivariate
analyses carried out on complete
cases only (n = 101, 44% of
participants). Data from full sample
included in multivariate analysis
taking into account random missing
data. AOR stratified by NSP status
not reported.
P-values not provided for bivariate
analysis of reported prevalence of
sharing ‘cooker, cotton, or water’
according to NSP use over time.
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Table 1: Summary of studies included in review following appraisal (Continued)
Stoltz et al.
2007 [22]
Cohort Vancouver,
Canada.
Recruitment:
2004 - 2005
Random sample of IDU
attending a medically
supervised injection facility (SIF).
760 IDU who completed a
follow up survey between 1st
July 2004 and 30th June 2005.
Frequent SIF users (n = 433)
were defined as those who
used the SIF for some, most or
all of their injecting episodes (i.
e. > 25% of all injecting
episodes) in the month prior to
interview. Infrequent SIF users
(n = 327) used the facility for <
25% of injecting episodes. SIF
use determined at baseline.
Participation rate not reported.
Facility provided a location to
inject drugs intravenously under
the supervision of a nurse,
advice on safe injecting
practices, referral to health care
and addiction services and
medical intervention in the
event of an overdose. IDU paid
to participate. Paraphernalia
provided included alcohol
swabs, sterile water and
cookers.
Exposure: SIF use (frequent vs.
infrequent) defined at study
enrolment.
Outcome: Self-reported change
in using clean water for
injecting since using the SIF.
Data collected by interview
administered questionnaire at
baseline and 6 month follow-
up.
Baseline classification of SIF use may
not represent SIF use at follow up.
Dichotomous measure of SIF use
does not allow for gradations in use.
Losses to follow up not
documented although authors
report no difference in the baseline
characteristics of the cohort
according to follow up status.
Self-reported outcome measures.
Vlahov et al.
1997 [23]
Cohort Baltimore,
USA.
Recruitment:
1994 - 1995
Systematic sampling of all self-
reported IDU enrolled in the
NSP during the first year of
operation. 422 IDU completed
baseline interviews (14.2% of all
individuals enrolled in the NSP).
IDU paid to participate. NSP
provided injection kits
containing alcohol wipes,
cotton and cookers.
Exposure: NSP use (before and
after establishment of NSP).
Outcome: Self-reported sharing
of cookers or cottons in the
preceding 2 weeks.
Data collected by interview
administered questionnaire at
baseline (NSP inception), 2
weeks and 6 months
Self-reported outcome measures.
Unadjusted analyses only.
No comparison group.
Follow up 79.4% (n = 335) at 2
weeks, 52.4% (n = 221) at 6 months.
Individuals lost to follow up differed
with respect to injecting risk
behaviours from those with
complete data.
Bluthenthal
et al. 1998
[24]
Serial Cross-
Sectional
Studies
California,
USA.
Recruitment:
1992 - 1995
Targeted sample of IDU aged
18 years or older reporting
injecting drug use in the
preceding 30 days, recruited by
street outreach and snowballing
techniques. Verification of
recent IDU required. Individuals
who participated were
encouraged to return on
subsequent semi-annual waves.
Total of 1034 IDU interviewed
once with 53% (n = 684)
returning for one or more
follow up visit. Setting: Illegal
NSP. NSP users had used the
NSP in the 30 days prior to
interview to obtain injecting
equipment and NSP was the
usual source of syringes in the 6
months prior to interview. NSP
provided alcohol and cotton
filters. Individuals who had
received other risk reduction
supplies such as cottons and
cookers from any HIV provider
in the 30 days prior to interview
were identified.
Exposure: NSP use (NSP users vs.
non-users and trends over
time).
Outcome: Self-reported sharing
of ‘cookers, cottons or rinse
water’ in the 30 days prior to
interview. A composite
outcome of sharing injection
supplies was used to indicate
the self-reported sharing of any
single item of non- N/S
paraphernalia.
Data collected by interview
administered questionnaire in
seven semi-annual waves.
Participants only had access to
cottons and alcohol wipes from NSP
thereby limiting the ability to
interpret results.
Convenience sampling.
Self-reported outcome measures.
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Table 1: Summary of studies included in review following appraisal (Continued)
Morissette
et al. 2007
[25]
Cross-
sectional
Montreal,
Canada.
Recruitment:
2004 - 2005
Convenience sample of IDU (n
= 275) aged 18 years or older
who had injected at least once
in the last 6 months recruited
by flyers, peer referral and
onsite personnel at three large
NSP. Verification of recent
injecting required. Participation
rate not reported.
IDU paid to participate. NSP
distributed sterile water and
Securicup kits containing
cooker, filter and swabs.
Exposure: Use of sterile non-N/S
injecting equipment (frequent
vs. infrequent).
Outcome: Self-reported sharing
of drug preparation equipment
(cookers, filters, water) in the
preceding 6 months (yes/no),
and frequency of use of sterile
cookers, filters and water in the
preceding month, HCV status.
Source of sterile injecting
equipment and reasons for not
using sterile equipment in the
past 6 months.
Data collected by interview-
administered questionnaire.
Convenience sample.
Self-reported outcome measures.
Longshore
et al. 2001
[26]
Cross-
sectional
Rhode
Island, USA.
Recruitment:
1997 - 1998
Convenience sample of IDU
over the age of 18 yrs old
attending NSP or MMT.
248 IDU (participation rate 70%).
IDU paid to participate. NSP
supplied cotton, cookers,
alcohol wipes and rinse water.
Exposure: NSP use (frequent vs.
infrequent use).
Outcome: Self-reported sharing
of cooker or other items of
injecting paraphernalia in the 6
months prior to interview and
frequency of visits to NSP.
Responses treated as categorical
variable.
Data collected by interview
administered questionnaire.
Convenience sample.
Self-reported outcome measures.
No comparison group.
Kipke et al.
1997 [27]
Cross-
sectional
California,
USA.
Recruitment:
1994
Convenience sample of IDU
aged 16-24 years who had
injected at least once during
the last 30 days. 89 NSP users
recruited through NSP (mobile
van). 109 non-users (poorly
characterised) recruited by
street outreach and using
snowballing techniques.
Participation rate not provided.
IDU paid to participate. NSP
provided water, cotton, cookers,
alcohol wipes.
Exposure: NSP use (NSP users vs.
non-users).
Outcome: Self-reported sharing
of ‘cookers, cottons or rinse
water’ in the preceding 6
months.
Data collected during semi-
structured interview.
Convenience sample.
Differential sampling methods
between NSP users and non NSP
users.
Flawed assessment of exposure to
NSP and access to paraphernalia.
NSP non-users poorly characterised.
Self-reported outcome measures.
Sears et al.
2001 [28]
Cross-
sectional
San
Francisco,
USA.
Recruitment:
July - Sept.
1997
Convenience sample of IDU
aged 15-25 years who had
injected drugs in the last 30
days and had experienced
homelessness within the last 30
days. Recruitment in two areas
of city: one in which a
secondary exchange
programme operated
(intervention site) and a
comparison site near which two
NSP operated. 67 IDU recruited
from the intervention site and
55 from the comparison site
(100% participation). IDU paid
to participate. Secondary syringe
exchange programme led by 4
peer exchangers provided
cookers, filters, water and
alcohol swabs. Items of
paraphernalia provided by other
NSP unclear.
Exposure: Access to secondary
syringe exchange vs. access to
other NSP (comparison based
site of recruitment).
Outcome: Self-reported sharing
of cookers in the preceding 30
days.
Data collected during structured
interview.
Convenience sample.
Almost 90% of study population
used NSP. In the comparison group
almost 40% reported obtaining
sterile paraphernalia from secondary
exchange, half from a recognised
formal NSP, a quarter from an
underground NSP and three
quarters via satellite distribution.
Self-reported outcome measures.
Results of adjusted analysis not
presented.
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from enrolment in a newly established NSP in Balti-
more, USA over a six month period [23]. The authors
observed a significant reduction in the proportion of
participants that reported sharing cotton filters in the
two weeks prior to interview, from 46% at baseline to
31% at six month follow up visit (P < 0.001). This trend
was also observed for cooker sharing, for which the cor-
responding values were 59% and 39%, respectively (P <
0.001). Adjusted analyses were not presented.
Serial Cross-sectional Studies
Bluthenthal et al conducted serial cross-sectional studies
in seven semi-annual waves over a three year period in
two neighbourhoods in California, USA in which an ille-
gal NSP distributed injecting kits containing alcohol
wipes and cotton filters [24]. Between the first and last
waves there was a statistically significant reduction in
the reported prevalence of sharing ‘other injection sup-
plies’ (cookers, filters or rinse water) in the preceding
Table 1: Summary of studies included in review following appraisal (Continued)
Heimer et
al. 2002
[29]
Cross-
sectional
Multi-site
study
Connecticut,
California,
Illinois, USA.
Recruitment:
1998 - 2000
Targeted sample of IDU aged
18 years or older reporting
injecting drug use in the
preceding 30 days, recruited by
street outreach and modified
snowballing.
493 IDU (n = 122 NSP users, n
= 371 NSP nonusers).
Participation rate not provided.
NSP provided water but unclear
whether other items of injecting
paraphernalia such as cookers
or filter were provided.
Exposure: NSP use (NSP users vs.
non-users).
Outcome: Self-reported sharing
of cookers, cottons, rinse water
or drug water in the 30 days
prior to interview. In addition
information on HIV and
hepatitis knowledge was
collected.
Data collected during semi-
structured interview
NSP users and nonusers not clearly
defined.
Paraphernalia provided by NSP
poorly defined.
Convenience sampling.
Self-reported outcome measures.
Cohort study but cross-sectional
data only presented.
Unadjusted analyses comparing
sharing of injecting paraphernalia
among NSP users and nonusers
only.
Guydish et
al. 1998
[30]
Cross-
sectional
San
Francisco,
USA.
Recruitment:
October
1994
Systematic sampling of all self-
reported IDU attending multi-
site NSP. Study population
poorly characterised.
143 IDU recruited of whom 114
(80%) participated. IDU paid to
participate.
NSP distributed cotton and
alcohol wipes.
Exposure: NSP use
Outcome: Self-reported sharing
of rinse water in the 30 days
prior to interview. The sharing
rinse water selected to
represent all ‘indirect’ sharing.
Also collected information on
the proportion of all needles
used by a client that came from
the NSP and frequency of visits
to NSP in last 30 days.
Data collected by interview
administered questionnaire.
Rinse water was selected to
represent all ‘indirect’ sharing; NSP
did not distribute rinse water
thereby limiting the ability to
interpret results.
Study population poorly
characterised.
Self-reported outcome measures.
Only unadjusted analyses presented.
No comparison group.
Colon et al.
2009 [31]
Non-
randomised
intervention
study (pilot)
Puerto Rico,
USA.
Recruitment:
16 week
intervention
period of
recruitment
not
described
Targeted sample of IDU aged
18 years or older reporting
injecting drug use in the
preceding 7 days recruited by
street outreach. 37 IDU (70%
participation).
16 week community level
intervention aimed at modifying
injecting risk behaviours. IDU
provided with injection kits that
included hand sanitizer, sterile
water in a water bottle and
syringe filter and advised on
use.
Exposure: Community level
intervention (see study
population)
Outcome: Self-reported change
in injecting practices in the
preceding 7 days: use of hand
sanitizer, use of water bottle
and use of syringe filter
provided in intervention, use of
non-study materials including
water and cookers. Self-reported
sharing of cooker during last
day of injection.
Data collected by interview
administered questionnaire. Pre
and post intervention data
collected by structured
interview. Analysis of
systematically sampled water
bottles and cookers for the
presence of red blood cells.
Samples collected from
shooting galleries 4 and 1
weeks prior to intervention and
8, 14 and 18 weeks following
commencement of the
intervention.
Non-randomised, uncontrolled study
design
Convenience sample.
Pilot study with small numbers
therefore unable to generalise
findings to other populations.
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Table 2 Summary of main research findings of studies included in review
Reference Paraphernalia Exposure Outcome Measure Measure of
Association
Hagan et al.
2000 [19]a
Cooker or
Filter
NSP users vs. nonusers AOR (95%CI) of sharing paraphernalia with adjustment
for heroin injection, frequency of injection, and syringe
or cooker/cotton sharing or back loading
0.79 (0.58 - 1.08)
Huo et al.
2007 [20]a
Cooker, Filter
or rinse water
NSP users vs. nonusers Proportion of participants reporting sharing
paraphernalia (behaviour at baseline to behaviour at 3
year follow up)
NSP users: 60% to
~22%
NSP nonusers:
70% to ~22%
Huo et al.
2007 [20]a
Cooker, Filter
or rinse water
NSP users vs. nonusers AOR (95%CI) of sharing paraphernalia with adjustment
for year recruited, age, race, heroin or cocaine injection,
injecting with others at least half the time, injecting in
semi-public settings, injecting in shooting gallery, and
having an IDU sex partner
0.70 (0.52 - 0.95)
Sears et al.
2001 [21]a
Cooker, Filter
or rinse water
NSP users vs. nonusers
(complete case analysis, n = 101)
Proportion of participants reporting sharing
paraphernalia (behaviour at baseline to behaviour at 1
year follow up)
NSP users: 61% to
45%
NSP nonusers:
40% to 30%
Stoltz et al.
2007. [22]a
Water Frequent SIF user vs. infrequent SIF
user
AOR (95%CI) of using clean water for injecting with
adjustment for age, gender, sex trade involvement, daily
cocaine and heroin injection
2.99 (2.13 - 4.18)
Vlahov et al.
1997 [23]a
Cooker Pre- vs. post-enrolment in NSP Proportion of participants reporting sharing
paraphernalia
(at baseline and at 6 months)
59% to 39% d
Vlahov et al.
1997 [23]a
Filter Pre- vs. post-enrolment in NSP Proportion of participants reporting sharing
paraphernalia
(at baseline and at 6 months)
46% to 31% d
Bluthenthal
et al. 1998
[24]
Cooker, Filter
or rinse water
Temporal trends in prevalence of
sharing paraphernalia
Proportion of participants reporting sharing
paraphernalia between wave 1 (1992) and wave 7 (1995)
~62% to ~40% d
Bluthenthal
et al. 1998
[24]
Cooker, Filter
or rinse water
Receipt of sterile injecting
paraphernalia in last 30 days vs. not
AOR (95%CI) of sharing paraphernalia with adjustment
for wave of study recruitment, gender, neighbourhood,
homelessness, HIV status, race, age, frequency of
injection and drug preference.
1.11 (0.89 - 1.39)
Bluthenthal
et al. 1998
[24]
Cooker, Filter
or rinse water
NSP users vs. nonusers AOR (95%CI) of sharing paraphernalia with adjustment
for wave of study recruitment, gender, neighbourhood,
homelessness, HIV status, race, age, frequency of
injection and drug preference.
0.85 (0.68 - 1.07)
Morissette
et al. 2009
[25]
Cooker Use of sterile injecting equipment ‘half
the time or more’ vs. ‘less than half the
time’ in the last month
OR (95%CI) of sharing drug preparation equipment in
the last 6 months
0.42 (0.22 - 0.80)
Morissette
et al. 2009
[25]
Filter Use of sterile injecting equipment ‘half
the time or more’ vs. ‘less than half the
time’ in the last month
OR (95%CI) of sharing drug preparation equipment in
the last 6 months
0.52 (0.28 - 0.97)
Morissette
et al. 2009
[25]
Water Use of sterile injecting equipment ‘half
the time or more’ vs. ‘less than half the
time’ in the last month
OR (95%CI) of sharing drug preparation equipment in
the last 6 months
0.51 (0.29 - 0.90)
Morissette
et al. 2009
[25]
Cooker Use of sterile injecting equipment ‘half
the time or more’ vs. ‘less than half the
time’ in the last month
AOR (95%CI) of being HCV negative vs. HCV positive
(self-reported) adjusted for age, gender, education,
injecting heroin as a primary drug, daily injecting,
injecting alone, requiring help with injecting and
problems obtaining sterile equipment from a NSP
3.92 (1.58 - 9.70)
Morissette
et al. 2009
[25]
Filter Use of sterile injecting equipment ‘half
the time or more’ vs. ‘less than half the
time’ in the last month
AOR (95%CI) of being HCV negative vs. HCV positive
(self-reported) adjusted for age, gender, education,
injecting heroin as a primary drug, daily injecting,
injecting alone, requiring help with injecting and
problems obtaining sterile equipment from a NSP
No association g
Morissette
et al. 2009
[25]
Water Use of sterile injecting equipment ‘half
the time or more’ vs. ‘less than half the
time’ in the last month
AOR (95%CI) of being HCV negative vs. HCV positive
(self-reported) adjusted for age, gender, education,
injecting heroin as a primary drug, daily injecting,
injecting alone, requiring help with injecting and
problems obtaining sterile equipment from a NSP
2.93 (1.12 - 7.68)
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six months (from an estimated 62% to 40% respectively;
P < 0.001) and a concurrent increase in the proportion
of those who reported receiving ‘other injection supplies’
from an HIV prevention provider (from an estimated
18% to 24%, P < 0.004) as well as an increase in
reported NSP use (from 5% to 36% respectively; P <
0.001). However, the study found no statistically signifi-
cant difference in the odds of sharing ‘other injection
supplies’ in the preceding 30 days among those who
reported receiving sterile injecting paraphernalia in the
preceding 30 days compared to those who did not
(AOR 1.11, (0.89-1.39)) (Table 2). Nor was there a sta-
tistically significant difference in the sharing of ‘other
injection supplies’ in the preceding 30 days between
those who reported NSP use and those who did not
(AOR 0.85 (0.68-1.07)).
Cross-sectional Studies
The only study identified in this review that correlated
the use of sterile non- N/S injecting paraphernalia to
(self-reported) HCV infection examined a convenience
sample of predominantly male, cocaine injecting IDU (n
Table 2: Summary of main research findings of studies included in review (Continued)
Longshore
et al. 2001e
[26]
Cooker NSP attendance > 4 times vs. once or
less/month
AOR (95%CI) of sharing paraphernalia with adjustment
for age, race, sex, injection frequency, primary drug, and
treatment experience.
0.39 (0.16 - 0.95)c
Longshore
et al. 2001e
[26]
Cooker NSP attendance > 4 times vs. 2-4
times/month
AOR (95%CI) of sharing paraphernalia with adjustment
for age, race, sex, injection frequency, primary drug, and
treatment experience.
0.50 (0.28 - 0.89) c
Longshore
et al. 2001e
[26]
Filter NSP attendance > 4 times vs. once or
less/month
AOR (95%CI) of sharing paraphernalia with adjustment
for age, race, sex, injection frequency, primary drug, and
treatment experience.
0.64 (0.27 - 1.52)
Longshore
et al. 2001e
[26]
Filter NSP attendance > 4 times vs. 2-4
times/month
AOR (95%CI) of sharing paraphernalia with adjustment
for age, race, sex, injection frequency, primary drug, and
treatment experience.
0.88 (0.49 - 1.59)
Kipke et al.
1997 [27]
Cooker, Filter
or rinse water
NSP users vs. nonusers AOR (95%CI) of sharing paraphernalia with adjustment
for age, gender and ethnicity
0.53 (0.28 - 0.99)c
Sears et al.
2001 [28]
Filter Intervention site vs. comparison sitef AOR (95%CI) of using someone else’s cotton with
adjustment for age, race/ethnicity, illegal/marginal
income source, use of drop-in centre, and number of
times consumed alcohol in the past 30 days
No association g
Heimer et
al. 2002.
[29]
Cooker NSP users vs. nonusers Proportion of participants reporting sharing
paraphernalia in last 30 days
9% vs.12% b
Heimer et
al. 2002.
[29]
Filter NSP users vs. nonusers Proportion of participants reporting sharing
paraphernalia in last 30 days
6% vs.8% b
Heimer et
al. 2002.
[29]
Rinse water NSP users vs. nonusers Proportion of participants reporting sharing
paraphernalia in last 30 days
3% vs. 9% d
Heimer et
al. 2002.
[29]
Drug water NSP users vs. nonusers Proportion of participants reporting sharing
paraphernalia in last 30 days
3% vs.9% c
Guydish et
al. 2008
[30]
Cooker, Filter
or rinse water
NSP users who reported sharing rinse
water in preceding 30 days vs. those
who did not
Mean NSP visits in past 30 days 4.36 vs. 3.75 b
Guydish et
al. 2008
[30]
Cooker, Filter
or rinse water
NSP users who reported sharing rinse
water in preceding 30 days vs. those
who did not
Mean percent of syringes obtained from NSP 86% vs. 89% c
Colon et al.
2009 [31]
Water bottle Pre vs. post intervention (18 week
follow up)
Percentage of participants adopting injecting practices in
the preceding 7 days
0% vs 56%d,h
Colon et al.
2009 [31]
Syringe filter Pre vs. post intervention (18 week
follow up)
Percentage of participants adopting injecting practices in
the preceding 7 days
0% vs. 34%c,h
Colon et al.
2009 [31]
Cooker Pre vs. post intervention (18 week
follow up)
Percentage sharing cooker during last day of injection 16% vs. 6% b
acohort studies did not report risk ratios: see Results section for details, bnot significant, cP < 0.05, dP < 0.001, eodds ratios presented here use the group with
lower frequency of NSP use as the referent group (as compared to those presented in the text), fintervention site were recruited from an area in which a
secondary exchange operated, comparison site were recruited from another location near which two other NSP operated, g result not presented, hpractices
absent at baseline therefore p values for test against null hypothesis that proportions at follow up < 15%
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= 275) recruited from NSPs in Montreal, Canada [25].
Almost one quarter of the study population reported
using sterile cookers (23%) and filters (23%) and three
quarters (75%) using sterile water for half or more of all
injecting episodes in the preceding month. Over a third
(37%) reported sharing any non-N/S drug preparation
equipment (cookers, filters or water) in the 6 months
prior to interview. IDU who reported frequent (‘half the
time or more’ vs. ‘less than half the time’) use of sterile
cookers, filters and water in the month prior to inter-
view were less likely to report sharing these items of
paraphernalia in the preceding 6 months (AORs 0.42
(0.22 - 0.80)), 0.52 (0.28 - 0.97)) and 0.51 (0.29 - 0.90))
respectively). The overall prevalence of self-reported
HCV infection was 66%. Individuals reporting frequent,
compared to infrequent, use of sterile cookers (AOR
3.92 (1.58 - 9.70)) and water (AOR 2.93 (1.12 - 7.68)),
but not filters (AOR not provided), in the preceding
month were significantly more likely to be self-reported
HCV-negative.
Of the remaining cross-sectional studies, three [26-28]
undertook multivariate analyses, although only one
appropriately adjusted for potential confounding vari-
ables and presented the results [26]. Longshore et al
examined injecting risk behaviour according to fre-
quency of NSP attendance (once per month or less, two
to four times per month and more than four times per
month) [26]. Infrequent NSP users (once per month or
less) were significantly more likely to report sharing a
cooker in the preceding six months than frequent NSP
attendees (more than four times per month) (AOR 2.55
(1.05 - 6.17)). However there was no significant differ-
ence between infrequent and frequent NSP attendees in
self-reported sharing cotton filters in the preceding six
months (AOR 1.57 (0.66 - 3.75)), despite the NSP pro-
viding this item of paraphernalia. Kipke et al compared
injecting risk behaviours in the preceding six months in
a convenience sample of young IDU described as NSP
users and nonusers, although these groups were poorly
defined [27]. Following adjustment for age, gender and
ethnicity, NSP users were significantly less likely to
report ‘sharing cotton, cookers or water’ in the preced-
ing six months than nonusers (AOR 0.53 (0.28 - 0.99)).
Sears et al examined injecting risk behaviours in young
homeless IDU recruited from two areas in San Fran-
cisco, USA, an intervention site at which a peer-led sec-
ondary exchange programme was in operation (n = 67)
and a comparison site near which two sanctioned pri-
mary NSPs and one clandestine NSP were in operation
(n = 55) [28]. Participants recruited from the interven-
tion site were less likely to report using someone else’s
cotton in the 30 days prior to interview than partici-
pants recruited from the comparison site (27% vs. 49%,
p = 0.003). This difference did not, however, persist fol-
lowing adjustment for potential confounding variables
(AOR not reported).
Two further cross-sectional studies were reviewed
[29,30]. In their multisite study, Heimer et al reported
a statistically significant difference between the sharing
of water for drug preparation (3% vs. 9% respectively;
p < 0.001) and syringe rinsing (3% vs. 9% respectively;
p < 0.005) in the 30 days prior to interview between
NSP users and nonusers, but no difference in the shar-
ing of cookers (9% vs. 12% respectively) or filters (6%
vs. 8% respectively) between groups (p values not pro-
vided) [29]. Adjusted analyses according to NSP use
were not presented and it was noted that NSP had
recently aggressively begun distributing sterile water;
the other items of paraphernalia provided by NSP
were not described in detail. Finally, Guydish et al
described the frequency of NSP use and the mean per-
centage of syringes obtained from NSP in relation to
self-reported sharing of rinse water (a proxy measure
for the sharing of cookers, cottons or rinse water) in
the preceding 30 days [30]. The authors reported no
significant difference in the mean number of NSP vis-
its in the preceding 30 days among participants report-
ing sharing rinse water compared to those who did not
(4.36 vs. 3.75 visits to the NSP in the preceding 30
days respectively). However, those who shared rinse
water reported obtaining significantly less syringes
from an NSP (86%) compared to non-sharers (89%) (P
< 0.05).
Intervention study
Colon et al evaluated a non-randomized, uncontrolled
pilot study of a 16 week intervention that aimed to
reduce contamination of injecting paraphernalia through
the promotion of novel drug preparation practices and
devices (a water bottle with dropper for preparing drug
solution and rinsing syringes, a N/S pre-fitted with a
sterile filter and a hand sanitizer for cleaning hands and
injection sites) [31]. Two weeks following the end of the
intervention, 56% of study participants reported using
water from the water bottle in preparing drug solution,
53% using water from the bottle to rinse a syringe, 66%
using the hand sanitizer and 34% using the syringe with
pre-fitted filter for at least 75% of all injecting episodes
in the day prior to interview and ‘most of the time’ or
‘always’ in the 7 days prior to interview; levels indicating
potential for self-sustaining change in behaviours. There
was no statistically significant reduction in the reported
sharing of cookers in the week prior to interview
between baseline (16%) and follow up visits (6%) (p =
0.453). However a 66% reduction in the likelihood of
detecting red blood cells on items of paraphernalia
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(water containers and cookers) collected from shooting
galleries during the intervention, compared to prior to
the intervention, was reported.
Discussion
Summary of key findings
This review aimed to explore the evidence base around
the provision of non- N/S sterile injecting parapherna-
lia as an intervention in the primary prevention of
HCV among IDU. We did not identify any studies that
examined the relationship between the supply of
injecting paraphernalia other than N/S and biological
measures of HCV infection. One study related self-
reported HCV infection to the use of sterile cookers,
filters and water, finding that those who frequently
used sterile cookers and water but not filters were
more likely to self-reported negative HCV status than
those who infrequently used them [25]. Inferences
about temporality cannot be drawn from this study
due to its cross-sectional design. The remaining obser-
vational studies reported behavioural outcomes. Eight
studies presented adjusted odds ratios for the associa-
tion between exposure to an NSP or SIF and sharing
injecting paraphernalia other than N/S
[19-22,24,26-28]. Effect size estimates were suggestive
of a reduction in the odds of sharing injecting para-
phernalia other than N/S associated with exposure to
NSP or SIF, but confidence intervals were wide and
often included unity. One study found no significant
association between the receipt of non- N/S sterile
injecting paraphernalia and the sharing of these items
[24]. Studies that examined unadjusted temporal trends
in the prevalence of sharing non-N/S injecting para-
phernalia [20,21,23,24] reported significant reductions
over time, usually coinciding with an increase in NSP
use. However, the only study to report an adjusted
temporal trend found that prevalence rates of sharing
injecting paraphernalia other N/S were lower at each
time point in non-NSP users compared to NSP users
[21]. The authors report a greater decline over time in
non-NSP users compared to NSP users although data
to support this statement are not provided in the
manuscript.
Limitations of the current literature
The only non-observational study included in this
review was a non-randomized, uncontrolled pilot inter-
vention study with few participants and no long-term
follow up [31]. Whilst providing encouraging data to
support larger scale intervention trials, these results
should be interpreted with caution. Of the observational
studies, seven employed cross-sectional designs [24-30],
which are limited with regards to the causal inferences
that can be drawn. It is possible that IDU who engaged
in high risk behaviours were also less likely to use NSP
or SIF. In studies examining temporal trends in the pre-
valence of sharing non- N/S injecting paraphernalia
[20,21,23,24], changes in observed injecting practices
may be attributable to contemporaneous interventions,
such as the delivery of harm reduction advice through
NSP, SIF or other service providers.
A constraint exists between the aim of this review
and the primary aim of the studies we identified.
Examining the effect of providing sterile non-N/S para-
phernalia to IDU was often a secondary rather than
primary aim. This is reflected in the design, analyses
and reporting of these studies. Few studies actually
measured the provision or uptake of paraphernalia
and, with two notable exceptions [24,25], exposure to
NSP was invariably adopted as a proxy measure for
uptake of the injecting paraphernalia offered by NSP.
Three studies measured the frequency [22,26] or prob-
ability [19] of NSP (or SIF) use, but several studies
used a more crude binary measure of NSP “users and
non-users”. The distinction between NSP users and
non-users was often unclear and in some cases, both
individuals designated as NSP users and non-users had
access to the sterile paraphernalia under study
[20,24,27,28]. For example, in the study by Huo et al,
clean filters and water were distributed to all partici-
pants [20], whilst in the study by Sears and colleagues
participants were classified according to the site of
recruitment rather than reported NSP use. In the latter
study, use of “any NSP” was almost ubiquitous among
participants recruited from the intervention site and as
high as 80% of the participants recruited from the
comparison site [28]. Misclassification of exposure sta-
tus may have attenuated any observed association
between NSP use and injecting risk behaviours.
As has been shown in the studies included in this
review, the sharing of individual items of injecting para-
phernalia is often highly correlated. Half of all studies
selected the sharing of a single or multiple items of
injecting paraphernalia to represent all indirect sharing
in their analyses [19-21,24,27,30]. Huo et al for example
investigated the association between NSP use and the
sharing of ‘other injecting paraphernalia’, denoting shar-
ing of either a cooker, filter or rinse water [20]. Thus, it
is not possible, in this review, to isolate the impact of
paraphernalia provision on the sharing of any specific
item of paraphernalia.
All studies used interviewer administered question-
naires or structured interviews to ascertain injecting risk
behaviour and may therefore be subject to recall and
social desirability bias [19-30]. It is reported that IDU
reliably describe injecting risk behaviours [32] however
ethnographic studies suggest that IDU may not be aware
of episodes of indirect sharing [7]. Differential reporting
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of sharing practices could result in residual confounding
which would affect any reported association.
Only two studies recruited a random sample of IDU
[19,22]; the remaining studies adopted a targeted
[24,29,31], systematic sampling strategy [21,23,30] or
recruited convenience samples [20,25-27] and often offered
financial incentive to participants [19,21-23,25-28,30]. All
the studies identified were conducted in North America
and several examined specific groups of IDU (for example
homeless youth [28] or predominantly male, cocaine injec-
tors [25]), in particular settings or contexts (for example
SIF [22] or secondary syringe exchange programmes [28]).
IDU are not a homogeneous group. Differences in the pat-
terns of sharing of drug injecting equipment, the perceived
risks associated with this and use of NSP have been
reported according to key sociodemographic such as gen-
der [33]. In addition important differences in structural
and organisation components of NSP, the provision of and
access to health care and the wider socio-political climate
that may limit the generalisability of these findings to other
populations.
A number of studies failed to adjust for potential con-
founders [23,29,30], or adjusted for only socio-demo-
graphic characteristics in statistical analyses [27]. It is
likely therefore that any effect from these studies will be
subject to residual confounding. Effective sample sizes
of the included studies ranged from 32 to 1582. The lar-
ger studies [19,20,24] were able to estimate effect sizes
with more precision, but given that no sample size cal-
culations were presented, it is uncertain whether studies
were adequately powered to detect an effect. Addition-
ally, given that injecting behaviours were highly corre-
lated, it is possible that even the largest studies would
have had insufficient power to detect an association
between an isolated injecting risk behaviour and NSP
attendance. Indeed the largest of the cohort studies,
Hagan et al experienced substantial losses to follow-up
and analysed data on only 56% of all participants
enrolled at baseline which will have further reduced
ability to detect an association [19].
The wider context
There is limited evidence that HCV transmission occurs
through the indirect sharing of injecting paraphernalia
[13]. Nevertheless the theoretical risks of HCV transmis-
sion through this route have been recognised for over a
decade [11] and high rates of sharing other injecting
paraphernalia have consistently been reported. Indeed
the sharing of cookers, filters and water is often
reported to be much more common than the sharing of
N/S. Many of the challenges of undertaking research in
this area have been highlighted in the methodological
limitations of the studies included in this review. Harm
reduction interventions such as NSP are complex and as
such demonstrating the effectiveness of each active
component of the intervention is challenging. In addi-
tion, access to sterile injecting paraphernalia other than
N/S at NSP or other settings does not necessarily trans-
late into uptake or use of paraphernalia by IDU. Quali-
tative studies from the UK and elsewhere suggest that
many IDU do not fully appreciate the risks associated
with sharing non- N/S injecting paraphernalia [33].
Situational (convenience, ease of access) and social fac-
tors (knowledge of injecting partners, pooling of
resources) [25,33], and levels of satisfaction with, and
perceived ease of use of [25], sterile injecting equipment
are also important in determining use. A further chal-
lenge lies in demonstrating the impact of an interven-
tion on HCV transmission: the prevalence of HCV in
IDU populations is generally high, therefore identifying
a large cohort of HCV naïve IDU to prospectively study,
and ensuring low rates of attrition, can be difficult.
However new developments in the serosurveillance of
IDU [34,35] offer the potential to examine the impact of
interventions on recently acquired HCV infection using
a cross-sectional design [34,35].
Limitations of this review
Given the heterogeneity in study designs, settings, popu-
lations and outcomes, we have not been able to present
an overall measure of effect in this review. We con-
ducted a thorough search of the literature, including the
grey literature, to identify all potentially relevant mate-
rial. However a number of studies were excluded
because a detailed description of the injecting supplies
provided by NSP was not available; improved reporting
in primary studies may have yielded more evidence.
This review examined biological (prevalent and incident
HCV infection) outcomes, although this did not yield
any studies, and behavioural (injecting risk behaviours)
outcomes. It is important to acknowledge that the use
of sterile non- N/S injecting paraphernalia may have
additional benefits that have not been captured in out-
comes considered in this review; for example, the poten-
tial to reduce bacterial infections or to attract and
engage IDU who may not otherwise be in contact with
health services [18]. Policy decisions on the distribution
of non-N/S paraphernalia should not therefore be made
on the basis of evidence relation to HCV transmission
or injecting risk behaviour in isolation.
Conclusions
Current evidence suggests that attendance at NSP pro-
viding sterile non-N/S injecting paraphernalia may be
associated with reduced sharing of non-N/S injecting
paraphernalia. However, the evidence is limited by the
number and quality of the studies. Therefore robust
conclusions cannot be drawn in relation to the impact
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of providing non-N/S paraphernalia on injecting risk
behaviours. No studies were found to have examined
the impact of providing sterile non-N/S injecting para-
phernalia on the transmission of HCV. We have identi-
fied a critical gap in the literature. Future studies would
benefit from longitudinal designs, accurate measure-
ments of the exposure variable as opposed to the use of
proxy variables, adjustment for known and potential
confounders and should be adequately powered to
detect changes in injecting risk behaviour or incident
HCV infection between exposed and unexposed groups.
These data are critical to inform future public health
policy and guide decision making by service providers
and users.
Appendix 1
(Table 3).
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